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DOI 10.1016/j.ccr.2012.02.007SUMMARYIncreased translocation of intestinal bacteria is a hallmark of chronic liver disease and contributes to hepatic
inflammation and fibrosis. Here we tested the hypothesis that the intestinal microbiota and Toll-like receptors
(TLRs) promote hepatocellular carcinoma (HCC), a long-term consequence of chronic liver injury, inflamma-
tion, and fibrosis. Hepatocarcinogenesis in chronically injured livers depended on the intestinal microbiota
and TLR4 activation in non-bone-marrow-derived resident liver cells. TLR4 and the intestinal microbiota
were not required for HCC initiation but for HCC promotion, mediating increased proliferation, expression
of the hepatomitogen epiregulin, and prevention of apoptosis. Gut sterilization restricted to late stages of
hepatocarcinogenesis reduced HCC, suggesting that the intestinal microbiota and TLR4 represent thera-
peutic targets for HCC prevention in advanced liver disease.INTRODUCTION
Increased translocation of intestinal bacteria is common in
patients with chronic liver disease and causes characteristic
infectious complications in advanced disease stages (Cirera
et al., 2001; Schuppan and Afdhal, 2008; Tandon and Garcia-
Tsao, 2008). In addition, translocation of bacterial components
termed pathogen-associated molecular patterns (PAMPs) trig-
gers inflammatory responses through Toll-like receptors (TLRs)
in both early and late disease stages (Dolganiuc et al., 2007;
Fukui et al., 1991; Nolan and Leibowitz, 1978; Seki et al., 2007;Significance
Hepatocellular carcinoma (HCC) typically develops in chronic
setting are not well characterized. Our study demonstrates th
microbiota contributes to injury- and inflammation-driven tu
most previous studies that focused on inflammatory pathwa
LPS-TLR4 pathway promotes HCC by increasing proliferativ
resident liver cells. Our finding that gut sterilization efficiently
for clinically applicable HCC prevention strategies in patients
504 Cancer Cell 21, 504–516, April 17, 2012 ª2012 Elsevier Inc.Wiest and Garcia-Tsao, 2005). Moreover, PAMPs from the intes-
tinal microbiota and TLR4 contribute to liver fibrosis and cirrhosis
(Broitman et al., 1964; Rutenburg et al., 1957; Seki et al., 2007).
Notably, 80% of hepatocellular carcinomas (HCCs) develop in
fibrotic or cirrhotic livers as a consequence of chronic liver injury
(Fattovich et al., 2004; Luedde and Schwabe, 2011), with HCC
being the leading cause of death in patients with compensated
liver cirrhosis (Fattovich et al., 2004). However, pathways that
are responsible for the high rate of HCC development in the
chronically injured and fibrotic liver remain largely unknown.
Here, we hypothesize that inflammatory and fibrogenically injured livers, but mediators that promote HCC in this
at TLR4 activation by lipopolysaccharide from the intestinal
mor promotion but not to tumor initiation. Different from
ys in bone marrow-derived cells, our study finds that the
e and antiapoptotic signals in non-bone marrow-derived
prevents HCC even at very late stages may provide a basis
with chronic liver injury.
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Figure 1. TLR4 Contributes to Hepatocarci-
nogenesis
(A) Tlr4WT mice (n = 10) and Tlr4mut (n = 9) were
injected with DEN (100 mg/kg i.p.) at the age
of 12 weeks followed by six injections of CCl4
(0.5 ml/kg i.p.) and sacrificed 10.5 months after
DEN. Shown are tumor number, largest tumor
size, liver:body weight ratio, H&E sections, and
representative images.
(B) Tlr4WT (n = 14) and Tlr4mut mice (n = 15) were
treated with DEN followed by two injections of
CCl4. Gene expression and ALT and AST levels
were determined 48 hr after the second CCl4
injection. Fold induction in comparison to
untreated livers. Data are represented as means ±
SD. *p < 0.05. **p < 0.01.
See also Figure S1.
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The Intestinal Microbiota, TLR4, and HCCresponses induced by the gut microbiota and TLRs contribute
to hepatocarcinogenesis and might represent targets for HCC
prevention or treatment.
RESULTS
TLR4 Is Required for Hepatocarcinogenesis in the
Chronically-Injured Liver
To determine whether the known contribution of TLRs to hepatic
inflammation and fibrosis may set the stage for HCC develop-
ment, we subjected C3H/HeJ andC3H/HeOuJmice, which carry
a nonfunctional and the wild-type Tlr4, respectively, to a combi-
nation of diethylnitrosamine (DEN) and the hepatotoxin carbon
tetrachloride (CCl4). This model incorporates chronic injury,
inflammation, fibrogenesis, and CCl4-mediated increases of
endotoxin levels (Seki et al., 2007) and thus shares several
features with the microenvironment in which the majority of
human HCCs arise. Tumors developing by this regimen showedCancer Cell 21, 504–5typical features of HCC, and microarray
analysis revealed a characteristic HCC
expression profile with Afp, Gpc3, and
Cdkn2b among the most upregulated
genes with greater than 90-fold increase
in comparison to normal liver (data not
shown). TLR4-wild-type (Tlr4WT) and
TLR4-inactivated mutant (Tlr4mut) mice
had a similar tumor incidence (100% in
Tlr4WT mice and 78% in Tlr4mut mice,
p = 0.2105), but Tlr4mut mice displayed
a profound reduction of tumor number
and size and an almost normal liver:body
weight ratio 10.5 months after the initial
DEN injection (Figure 1A).
Taking advantage of the separate initi-
ation and promotion stages in this model,
we further analyzed the contribution of
TLR4 at these stages. Following DEN
injection, we observed no differences in
the induction of inflammatory genes Il6
and Ccl2 and p53-dependent genes
Cdkn1a and Bax between Tlr4WT andTlr4mut mice (Figure S1A available online). DEN-induced liver
injury, as determined by serum ALT and AST levels, was exacer-
bated in Tlr4mut mice (Figure S1A). However, the increased liver
injury is unlikely to cause decreased hepatocarcinogenesis
in Tlr4mut mice, as liver injury after DEN is thought to promote
hepatocarcinogenesis by inducing regenerative responses
(Maeda et al., 2005; Naugler et al., 2007). Moreover, despite
a small trend toward decreased HCC development, all Tlr4mut
mice subjected to a purely genotoxic hepatocarcinogenesis
protocol developed numerous large tumors (Figure S1B). Thus,
TLR4 status exerts no major effect on genotoxic tumor initiation
apart from an increased susceptibility of Tlr4mut mice to liver
injury. In contrast, we observed a significant impact of TLR4
status on tumor promotion by CCl4, with proliferation markers
mKi67, Pcna, Ccnb1, and Ccnb2; hepatic fibrogenesis markers
Col1a1 and Acta2; and inflammatory markers Il6, Il1b, Tnf, and
Ccl2 strongly reduced in Tlr4mut mice, as evidenced by microar-
ray (data not shown) and qPCR analysis, despite increased liver16, April 17, 2012 ª2012 Elsevier Inc. 505
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Figure 2. The Intestinal Microbiota
Promotes Hepatocarcinogenesis
(A) Wild-type (WT) mice (C3H/HeOuJ) were treated
with DEN plus six injections of CCl4 and either did
(n = 11) or did not (n = 7) receive antibiotics
(ampicillin, neomycin, metronidazole, and vanco-
mycin) in their drinking water starting 2 weeks
before and throughout the entire period. Shown
are representative images of ceca, tumors, and
H&E sections.
(B) Wild-type (WT) mice were treated with DEN
plus two injections of CCl4 and either did (Abx, n =
14) or did not (Ctrl, n = 9) receive the antibiotics
cocktail described in (A) 2 weeks before DEN
injection until they were sacrificed 48 hr after the
last CCl4 injection. Gene expression is expressed
as fold induction in comparison to untreated liver.
Liver injury was assessed by ALT and AST
measurements.
(C) Tlr4WT, Tlr4mut, and Tlr4WT mice treated with
antibiotics were injected with DEN and two
subsequent injections of CCl4 and sacrificed 48 hr
later. RNA of livers from untreated Tlr4WTmice (n =
3), DEN plus CCl4-treated Tlr4
WT (n = 4), DEN plus
CCl4-treated Tlr4
mut mice (n = 4), and antibiotics
plus DEN plus CCl4-treated Tlr4
WT mice (n = 4)
were used for microarray analysis. The left heat-
map shows changes of 1,752 genes in the Tlr4mut
and antibiotics-treated mice that were (a) at least
1.8-fold up- or downregulated by DEN plus CCl4
treatment in Tlr4WT mice in comparison to
untreated mice and (b) 1.8-fold up- or down-
regulated in DEN plus CCl4-treated Tlr4
mutmice in
comparison to DEN plus CCl4-treated Tlr4
WTmice.
The right heatmap shows genes fulfilling the same
conditions as described earlier restricted to the
GO categories 0007049, 0009611, and 0005578.
Data are represented as means ± SD. *p < 0.05.
**p < 0.01.
See also Figure S2.
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The Intestinal Microbiota, TLR4, and HCCinjury (Figure 1B; Figures S1C and S1D). Similar differences were
observed after DEN plus four CCl4 injections, suggesting
a lasting effect of absent TLR4 signaling (Figure S1D). While
CCl4 plus DEN-induced liver injury was increased in Tlr4
mut
mice 48 hr after the last CCl4 injection, it was similar to Tlr4
WT
at earlier time points (Figure S1E), suggesting that the Tlr4mut
mice have a defect in DEN plus CCl4-induced injury resolution
and wound healing rather than a higher susceptibility to the
initial injury. As chronic regeneration contributes to replication-
induced mutagenesis and HCC, we confirmed the reduction
of proliferation using Tlr4 knockout (Tlr4KO) mice in C57Bl/6
background and Ki-67 immunohistochemistry (Figures S1F
and S1G).
To exclude that our findings reflect a particular role for TLR4 in
the response to CCl4, we tested two additional models in which
DEN was combined with thioacetamide or a choline-deficient
diet and found essentially the same results with decreased prolif-506 Cancer Cell 21, 504–516, April 17, 2012 ª2012 Elsevier Inc.eration and fibrogenesis (Figures S1H–
S1J). We also tested whether TLR2,
which recognizes PAMPs from the gram-
positive bacterial microbiota, contributesto hepatocarcinogenesis. However, we did not find a role for
TLR2 in DEN plus CCl4-induced proliferation or HCC develop-
ment (Figures S1K and S1L).
The Intestinal Microbiota and Lipopolysaccharide
Promote Hepatocarcinogenesis
Next, we examined whether ligands from the bacterial intestinal
microbiota are triggers for the observed TLR4-dependent tumor
promotion. For this purpose, we gut-sterilized mice with a
well-established cocktail of oral antibiotics that eliminates
commensal bacteria (Rakoff-Nahoum et al., 2004) and reduces
systemic lipopolysaccaride (LPS) levels (Seki et al., 2007). This
treatment resulted in not only a >99.5% reduction of 16s levels
in the cecum (Figure S2A) and an enlargement of the cecum
commonly observed in germfree (GF) mice (Figure 2A) but also
a highly significant reduction of tumor number, size, and the
liver:body weight ratio in our DEN plus CCl4 HCC model
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Figure 3. LPS Promotes Hepatocarcino-
genesis but Does Not Change the Intestinal
Bacterial Microbiota
(A) Tlr4WT (C3H/HeOuJ) mice were treated with
DEN plus six injections of CCl4 and either received
LPS (300 mg/kg/d, n = 9) or PBS (n = 10) via
subcutaneous pumps starting 1 week before the
first CCl4 injection for 12 weeks. Mice were sacri-
ficed 8.5 months after DEN injection to determine
tumor number, size, and liver:body weight ratio.
*p < 0.05. **p < 0.01.
(B) Unifrac analysis of 16s sequencing results of
the cecal microbiome in Tlr4WT (n = 3) and Tlr4mut
(n = 4) mice, Tlr4WT mice treated with subcuta-
neous PBS (n = 4) or LPS (n = 4) pumps for
2weeks, or Tlr4WTmice receiving antibiotics (n = 4)
for 2 weeks.
(C) Taxonomic distribution of the cecal micro-
biome in Tlr4WT and Tlr4mut mice, Tlr4WT mice
treated with subcutaneous PBS or LPS pumps for
2 weeks, or mice receiving antibiotics for 2 weeks.
The chart contains a total of 118 taxa at the genus
level, and the top 20 taxa are annotated on the left
with most abundant taxa listed on top. Data are
represented as means ± SD. *p < 0.05. **p < 0.01.
See also Figure S3.
Cancer Cell
The Intestinal Microbiota, TLR4, and HCC(Figure 2A). Similar to data in the Tlr4mut mice, tumor incidence
was not affected by gut sterilization (100% in gut-sterilized vs.
100% in control mice). In addition to the similar degree of HCC
reduction, gut sterilization markedly phenocopied events
observed in the Tlr4mut mice such as reduced expression of
cell cycle, fibrosis, and inflammatory genes and increased liver
injury (Figure 2B; Figure S2B). Accordingly, the great majority
of 1,752 genes that were significantly up- or downregulated
by DEN plus CCl4 and significantly up- or downregulated by
TLR4 inactivation were concordantly regulated in DEN plus
CCl4-treated liver from gut-sterilized mice (r = 0.794, p <
0.0001), suggesting that TLR4 inactivation and gut sterilization
exert highly similar biological effects on the liver during hepato-
carcinogenesis (Figure 2C). Like Tlr4mut mice, gut-sterilized
mice also did not show differences in inflammatory and p53-
dependent gene expression in response to acute DEN treatment
but displayed increased liver injury (Figure S2C).
As a third approach in addition to TLR4 inactivation and gut
sterilization, we treated mice with a low, nontoxic dose of LPS
via subcutaneous osmotic pumps for 12 weeks during DEN
plus CCl4-induced hepatocarcinogenesis. This low-dose LPSCancer Cell 21, 504–5treatment led to a significant increase in
inflammatory gene expression, tumor
number, tumor size and liver:body weight
ratio (Figure 3A; Figure S3), further con-
firming our hypothesis that the LPS-
TLR4 pathway promotes hepatocarcino-
genesis. As Tlr5-deficient mice have an
altered gut microbiome (Vijay-Kumar
et al., 2010), it is conceivable that TLR4
might also affect the composition of the
gut microbiome and thereby influence
HCC development rather than exertingdirect effects in the liver. To address this possibility, we first
performed 16s-based pyrosequencing of the cecal gut micro-
biota of wild-type and Tlr4mut mice as well as mice treated
with PBS or LPS. Unifrac analysis revealed no significant differ-
ences between Tlr4WT and Tlr4mut mice, or between PBS- and
LPS-treated mice, but showed distinct clustering of the gut-
sterilized mice (Figure 3B). It is interesting that differences
between these two independent experiments were larger in the
Unifrac analysis than differences between Tlr4WT and Tlr4mut
mice, or PBS- and LPS-treated mice, again underlining that
LPS and TLR4 status exert no significant influence on the
composition of the gut microbiome. Moreover, the taxonomic
distribution of the cecal gut microbiome was similar between
Tlr4WT and Tlr4mut mice, and PBS- and LPS-treated mice (Fig-
ure 3C); among the 118 detected taxa at the genus level, we
found no significant differences between Tlr4WT and Tlr4mut
mice and only one taxon (firmicutes;bacilli;other;other;other)
with a significant but modest difference between PBS-treated
mice (8.1% abundance) and LPS-treated mice (4.7% abun-
dance). However, as there was no difference in this taxon
between Tlr4WT and Tlr4mut mice, it is extremely unlikely that16, April 17, 2012 ª2012 Elsevier Inc. 507
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Figure 4. GF Status Decreases Hepatocarcinogenesis
GF C57Bl/6 mice were subjected to DEN (25 mg/kg i.p.) injection, split into
SPF and GF groups, and then received 10 CCl4 (0.5 ml/kg i.p.) injections.
(A) Ceca of GF and SPFmice are shown on the far left, and representative livers
with tumors are shown on the right.
(B) Tumor number, size, and liver:body weight ratio was determined in SPF
mice (n = 9) and GF mice (n = 10). Data are represented as means ± SD.
*p < 0.05. **p < 0.01.
Cancer Cell
The Intestinal Microbiota, TLR4, and HCCthe different abundance of this taxon is responsible for differ-
ences in hepatocarcinogenesis.
As a fourth approach, we investigated DEN plus CCl4-induced
hepatocarcinogenesis in GF and littermate controls that had
been transferred to a specific-pathogen-free (SPF) environment
after the initial DEN injection. GF mice displayed the typical
enlargement of the cecum and had a significantly reduced tumor
number, tumor size, and liver:body weight ratio in comparison
to SPF mice (Figures 4A and 4B), thus confirming results in
mice gut-sterilized by antibiotics and excluding that effects of
antibiotics on the liver were responsible for HCC reduction.
Non-Bone-Marrow-Derived Resident Hepatic Cells
Mediate the Tumor-Promoting Effect of TLR4
To determine the hepatic cell that promotes HCC in response
to TLR4 activation, we generated TLR4-chimeric mice using
a combination of irradiation, bone marrow transplantation
(BMT), and liposomal clodronate-mediated macrophage deple-
tion (Seki et al., 2009; Seki et al., 2007). This protocol achieved
>97% suppression of LPS responses after transplantation of
Tlr4mut bone marrow into Tlr4WT mice, almost complete restora-
tion of LPS responses after transplantation of Tlr4WT bone
marrow into Tlr4mut mice, and substitution of F4/80-positive
hepatic macrophages (Figure S4A). DEN plus CCl4-induced hep-
atocarcinogenesis in TLR4-chimeric mice revealed no significant
reduction of HCC number, size, and liver:body weight ratio in
mice transplanted with Tlr4mut bone marrow, whereas TLR4
inactivation in resident (defined hereby as non-bone-marrow-
derived) liver cells significantly reduced HCC number, size, and
liver:body weight ratio (Figure 5A). Similarly, the induction of
mKi67 and Pcna mRNA in response to acute DEN plus CCl4
treatment was significantly reduced in Tlr4mut mice with Tlr4WT508 Cancer Cell 21, 504–516, April 17, 2012 ª2012 Elsevier Inc.bone marrow in comparison to Tlr4WT mice with Tlr4WT bone
marrow (Figure 5B). Moreover, the depletion of hepatic macro-
phages by liposomal clodronate did not affect the response
to DEN plus CCl4, as evident by mKi67 and Pcna mRNA levels
(Figure S4B). To determine the resident liver cell that was
responsive to LPS, we injected a sublethal dose of LPS into
healthy mice and mice that had undergone DEN plus eight
CCl4 treatments, followed by determination of NF-kB p65 trans-
location. To avoid the known rapid release of tumor necrosis
factor (TNF) and subsequent TNF-mediated NF-kB activation
as a cofounding factor, we used either (a) TLR4-chimeric mice
with Tlr4mut bone marrow, (b) macrophage-depleted mice, or
(c) mice deficient for both TNFR1 and IL-1R1 for this experiment.
In uninjured liver, we observed strong NF-kB p65 nuclear trans-
location in desmin-positive hepatic stellate cells and Kupffer
cells but no translocation in hepatocytes after LPS injection (Fig-
ure S4C). In mice that had undergone DEN plus CCl4 treatment,
we confirmed p65 nuclear translocation in hepatic stellate cells
but also observed p65 translocation in a large percentage of
hepatocytes (Figure 5C; Figure S4D), suggesting that both hepa-
tocytes and hepatic stellate are candidates for TLR4-dependent
tumor promotion in the chronically injured liver.
Epiregulin Is a TLR4-Regulated Hepatomitogen that
Promotes Hepatocarcinogenesis
Microarray analysis demonstrated cell cycle-related genes as
most significantly affected by TLR4 status or gut sterilization
(Figure 2C). Our microarray and subsequent qPCR analysis
revealed reduced expression of two hepatomitogens, HGF and
epiregulin (Toyoda et al., 1995), in livers from DEN plus CCl4-
treated Tlr4mut and gut-sterilized mice as well as from TLR4-
chimeric mice with Tlr4mut in resident liver and Tlr4WT bone
marrow (Figures 6A and 6C). Both HGF mRNA (data not shown)
and epiregulin mRNA were expressed much higher in hepatic
stellate cells than in whole liver, hepatocytes, or hepatic macro-
phages (Figure 6D). As the role of HGF in hepatocarcinogenesis
remains controversial (Sakata et al., 1996; Santoni-Rugiu et al.,
1996; Takami et al., 2007), we focused our attention on epiregu-
lin. Hepatic stellate cells isolated from fibrotic livers secreted
significantly more epiregulin than quiescent hepatic stellate cells
(Figure 6D), and stimulation of hepatic stellate cells with LPS
significantly upregulated epiregulin mRNA and protein in an
NF-kB dependent manner (Figure 6E). Moreover, LPS injection
into mice either as a bolus or via the aforementioned chronic
subcutaneous infusion also significantly increased epiregulin
expression in the liver (Figure 6D; Figure S3). Epiregulin mRNA
expression was also induced by LPS in human hepatic stellate
cells and upregulated in livers of patients with alcoholic hepatitis,
a group of patients with typically very high LPS levels (Fukui
et al., 1991) (Figure 6F).
To elucidate the contribution of epiregulin to hepatocarcino-
genesis, we subjected wild-type and epiregulin-deficient
(EregKO) mice to DEN plus CCl4-mediated hepatocarcinogene-
sis. Due to the much lower propensity of C57Bl/6 mice to
develop HCC, we used an altered protocol in which mice were
subjected to DEN at Day 15 postpartum, followed by multiple
CCl4 injections. Ereg
KO mice displayed a significant reduction
of tumor number, size, and the liver:body weight ratio, albeit to
a much lesser degree than Tlr4mut mice (Figure 6G). Moreover,
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Figure 5. Resident Liver Cells Mediate
TLR4-Dependent Tumor Promotion
(A) Tlr4WT and Tlr4mutmice were subjected to BMT
(n R 10 per group) at 8 weeks followed by treat-
ment with DEN plus eight injections of CCl4. Mice
were sacrificed 10.5 months after DEN. Shown
are representative images of tumors and H&E
sections, as well as tumor number, size, and
liver:body weight ratio.
(B) Tlr4WT (n = 7) and Tlr4mut mice (n = 6) were
transplanted with wild-type bone marrow and
treated with DEN plus two injections of CCl4 at
the age of 8 weeks. Proliferation markers were
evaluated by qPCR and shown as fold induction
in comparison to untreated mice.
(C) TLR4 chimeric mice with Tlr4WT resident cells
and Tlr4mut bone marrow (n = 3) were treated
with DEN plus CCl4 as described earlier. At
10.5 months after DEN, LPS (10 mg/kg i.v.) was
injected and NF-kB p65 nuclear translocation
was determined by immunohistochemistry and
confocal microscopy in nontumor liver areas.
Hepatic stellate cells were visualized by desmin
staining, and nuclei were visualized by Hoechst
staining. Green and white arrows indicate NF-kB
translocation in hepatic stellate cells and hepato-
cytes, respectively. The percentage of hepatic
stellate cells (HSC) and hepatocytes (Hep) with
positive nuclear p65 was determined. Data are
represented as means ± SD. *p < 0.05. **p < 0.01.
See also Figure S4.
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The Intestinal Microbiota, TLR4, and HCCepiregulin was not upregulated at late stages in our hepatocarci-
nogenesis model and did not differ between wild-type, Tlr4mut,
and gut-sterilized mice at these stages of hepatocarcinogenesis
(Figure 6H). Thus, additional factors must be responsible for the
striking reduction of hepatocarcinogenesis in Tlr4mut and gut-
sterilized mice.
The Intestinal Microbiota and TLR4 Suppress Apoptosis
in Late Stage of Hepatocarcinogenesis
Next, we attempted to establish the time frame during which
bacterial PAMPs exert the most profound effects on hepatocar-
cinogenesis. Surprisingly, gut sterilization during the first
4.5 months of hepatocarcinogenesis showed only a moderate
decrease of hepatocarcinogenesis (Figure 7A). In contrast, gut
sterilization during the last 4 months of hepatocarcinogenesis
reduced tumor number and size by 90% and 70%, respectively,
and almost normalized the liver:body weight ratio (Figure 7A). AtCancer Cell 21, 504–5this point, mice had not yet developed
macroscopically or microscopically
visible tumors (Figure 7B), suggesting
that gut sterilization prevented tumor
development rather than leading to the
regression of already established tumors.
We additionally tested whether more
selective gut decontamination with rifaxi-
min, a widely used nonabsorbable antibi-
otic for the prevention of hepatic enceph-
alopathy in patients with endstage liver
disease (Bass et al., 2010), could influ-ence hepatocarcinogenesis at late stages. We observed
a borderline significant reduction of tumor numbers but saw no
significant reduction in tumor size (data not shown), suggesting
onlymoderate efficacy of rifaximinmonotherapy on hepatocarci-
nogenesis at late stages (Figure S5).
To determine whether gut sterilization might affect already
established tumors, we treated wild-type mice at a time point
where tumors were already present with the quadruple antibi-
otics cocktail for 6 weeks. However, we found no significant
change of tumor size, number, or liver:body weight ratio in
comparison to control mice (Figure 7C). When following single
tumors by weekly ultrasoundmonitoring, we also saw no change
in tumor size in antibiotics-treated mice (data not shown).
To further determine the mechanism by which the intestinal
microbiota and TLR4 promote hepatocarcinogenesis, we
analyzed gene expression, proliferation, and apoptosis in gut-
sterilized and Tlr4mut mice. Due to the lower tumor number16, April 17, 2012 ª2012 Elsevier Inc. 509
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Figure 6. Epiregulin Is an LPS-Inducible
Promoter of Hepatocarcinogenesis
(A) Ereg and HgfmRNAwere determined in Tlr4mut
mice (n = 14), Tlr4mut (n = 15) and antibiotics-
treated Tlr4WT (n = 9) after DEN and 23 CCl4
injections. Fold induction versus untreated livers.
(B) Ereg and HgfmRNA were determined in TLR4-
chimeric mice with Tlr4WT resident cells and Tlr4WT
bone marrow (n = 6) or Tlr4mut resident cells and
Tlr4WT bone marrow (n = 6) after treatment with
DEN and two CCl4 injections. Fold induction
versus untreated livers.
(C) Western blot of HGF from Tlr4WT mice, Tlr4mut
mice, and antibiotics-treated mice after DEN and
23 CCl4 injections.
(D) Hepatocytes (Hep), Kupffer cells (KC), and
hepatic stellate cells (HSC) were isolated from liver
treated with DEN and two injections of CCl4
followed by analysis of Ereg mRNA expression
by qPCR (left panel). Shown is a fold induction
versus whole liver. EregmRNAwas isolated in liver
extracts from CCl4-treated mice injected with LPS
(10 mg/kg i.v.) or PBS 4 days after the last CCl4
injection (second panel from left). Activated
hepatic stellate cells were isolated from CCl4-
treated and bile duct-ligated livers. Epiregulin was
determined by ELISA 24 hr after plating.
(E) Hepatic stellate cells from DEN plus 23 CCl4
treated mice were stimulated with LPS (100 ng/ml)
in the presence of either an adenoviral IkB super-
repressor (AdIkBsr) or empty shuttle virus (AdSh)
by qPCR (left panel) or ELISA (right panel).
(F) EREG expression was determined in normal
liver (NL, n = 4) and livers of patients with alcoholic
hepatitis (AH, n = 10, left panel) and in activated
human hepatic stellate cells stimulated with LPS
(100 ng/ml, right panel).
(G) Wild-type (WT, n = 11) and EregKOmice (n = 14)
were treated with DEN plus 22 injections of CCl4.
Mice were sacrificed 6.5 months after DEN.
Shown are representative images of tumors as
well as tumor number, size of the largest tumor,
and liver:body weight ratio.
(H) Ereg expression was analyzed in nontumorous
regions of DEN plus CCl4-treated Tlr4
WT (n = 12),
Tlr4mut (n = 9), and antibiotics-treated Tlr4WT (n = 6)
mice 10.5months after DEN. Fold induction versus
untreated liver. Data are represented as means ±
SD. *p < 0.05. **p < 0.01. nd, nondetectable.
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The Intestinal Microbiota, TLR4, and HCCand size, the overall amount of Ki-67 staining in Tlr4mut and gut-
sterilized mice was expectedly lower (data not shown). Microar-
ray comparison showed a highly similar gene expression pattern
in HCC from wild-type, Tlr4mut, and gut-sterilized mice (Fig-
ure S6A), and HCCs from these groups did not cluster separately
as shown by dendrogram and Unifrac analysis (Figures S6B-
S6C). There was a small but nonsignificant trend toward lower
AFP and Ki-67 in HCCs from gut-sterilized mice and Tlr4mut
mice, which was most likely due to the smaller size of the tumors
in these groups. There were no genes that showed significant
changes, as defined by a corrected p value of < 0.05, in the
Tlr4mut or gut-sterilized HCC groupwhen compared to the Tlr4WT
HCC group (data not shown). Moreover, there were no differ-
ences in tumor grade (Figure S6D), and there was a similar loss
of collagen IV staining in HCCs from all groups (Figure S6E).510 Cancer Cell 21, 504–516, April 17, 2012 ª2012 Elsevier Inc.Microarray analysis showed no differences in expression of the
cancer stem cell marker prominin 1/CD133 (data not shown),
and we found only small and very rare clusters of cells positive
for the progenitor marker A6 (Engelhardt et al., 1990), withmostly
low A6 expression andmorphology of intermediate hepatobiliary
cells (Figure S6F). Similarly, there were only few cells with strong
pan-cytokeratin signal typical for oval cells in tumors of all
treatment groups and a larger but highly variable amount of cells
with weak pan-cytokeratin expression typical of intermediate
hepatobiliary cells in all groups (Figures S6G-S6H). Altogether,
the microarray and immunohistochemical data suggest that
TLR4 signaling is unlikely to promote hepatocarcinogenesis via
progenitor cells. There was also no significant difference in
Ki-67 positive cells in nontumor liver between these groups,
suggesting that TLR4 and the intestinal microbiota do not
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(A) Wild-type mice (C3H/HeOuJ) were treated with
DEN (100 mg/kg i.p. at the age of 6 weeks) and 12
CCl4 (0.5 ml/kg i.p.) injections and were either not
gut sterilized (N, n = 7), gut sterilized starting
2 weeks before DEN injection until 2 weeks after
the last CCl4 injection (E, n = 10), or 2 weeks after
the last CCl4 injection until they were sacrificed
(L, n = 8), followed by determination of tumor
number, size, and liver:body weight ratio.
(B) Wild-type mice treated as described earlier
were sacrificed at the time point when the gut-
sterilization treatment was started to determine
whether macroscopic or microscopic tumors were
present.
(C) Wild-type mice were treated with DEN
(25 mg/kg i.p.) at Day 15 postpartum followed by
14 weekly injections of CCl4. After confirming the
presence of tumor by ultrasound (data not shown),
mice were treated with (Abx, n = 7) or without
(Ctrl, n = 6) antibiotics (ampicillin, vancomycin,
neomycin, and metronidazole) starting 2 weeks
after the last CCl4 injection. After 6 weeks of anti-
biotics, mice were sacrificed, and tumor number,
size, and liver:body weight ratio was determined.
Data are represented as means ± SD. *p < 0.05.
**p < 0.01. ns, nonsignificant.
See also Figure S5.
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The Intestinal Microbiota, TLR4, and HCCpromote tumor formation by increasing proliferation in nontumor
liver (Figure 8A).
Both gut-sterilized and Tlr4mut mice displayed a significant
increase in cleaved-caspase 3-positive cells with predominant
expression of cleaved-caspase 3 in hepatocytes in nontumor
areas (Figure 8B). Notably, the number of cleaved caspase 3-
positive cells was inversely and highly significantly correlated
with tumor number, size, and the liver:body weight ratio (Fig-
ure 8B), further underlining the biological relevance of these
findings. Significant increases in cleaved-caspase 3 positive
cells and a strong and highly significant inverse correlation
between cleaved-caspase 3 and tumor number, size, and
liver:body weight ratio were also observed in mice that were
gut-sterilized at late time points (Figures 8C and 8D). Moreover,
the expression of NF-kB-regulated antiapoptotic genes Birc3,
Birc5, and Nos2 (Hatano et al., 2001; Wang et al., 1998) was
reduced in nontumor areas of livers from Tlr4mut and antibi-
otics-treated mice (Figure 8E), suggesting that TLR4 and the
intestinal microbiota provide survival signals that are advanta-
geous for hepatocarcinogenesis.
DISCUSSION
Chronic inflammation is a key contributor to carcinogenesis in
variousorgans including thestomach, colon, lung, and liver (Balk-Cancer Cell 21, 504–5will and Mantovani, 2001; Grivennikov
et al., 2010). In the liver, 80% of HCCs
develop in amicroenvironment character-
ized by chronic injury, inflammation, and
fibrosis. However, mediators that areresponsible for the high risk to develop HCC in the chronically
injured liver are largely unknown. Translocation of bacteria
and bacterial PAMPs is common in chronic liver disease (Schup-
pan and Afdhal, 2008; Tandon and Garcia-Tsao, 2008) and
promotes inflammation and fibrosis in chronic liver injury (Seki
et al., 2007).
We now provide several lines of evidence that the intestinal
microbiota and TLR4 link inflammation and carcinogenesis
in the chronically injured liver. Genetic TLR4 inactivation, gut
sterilization, or GF status decrease HCC development by
z80%. Conversely, prolonged treatment with low-dose LPS
significantly increases HCC development. These findings are
similar to intestinal tumorigenesis in which TLR4 and MyD88
drive carcinogenesis (Fukata et al., 2007; Lee et al., 2010; Rak-
off-Nahoum and Medzhitov, 2007). In contrast to the intestine,
the liver is not in direct contact with intestinal bacteria. However,
the liver is the first target of intestinal bacteria and PAMPs
translocating into the portal circulation. Moreover, translocation
increases with the development of liver fibrosis and cirrhosis
(Fukui et al., 1991; Lin et al., 1995; Wiest and Garcia-Tsao,
2005). Our HCC data in GF mice effectively exclude the possi-
bility that the employed antibiotics with low systemic bio-
availability might have exerted direct effects on the liver in our
model. Moreover, 16s pyrosequencing demonstrated that
TLR4 status and LPS treatment do not significantly change16, April 17, 2012 ª2012 Elsevier Inc. 511
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Figure 8. TLR4 and the Intestinal Microbiota
Protect from Apoptosis
(A–B) Livers from Tlr4WT (n = 11), Tlr4mut (n = 9) or
antibiotics-treated (Abx) Tlr4mut mice (n = 7) were
stained for Ki-67 (A) or cleaved-caspase 3 (B)
followed by quantification. Correlation between
the number of cleaved-caspase 3 positive cells
and tumor number, size and liver:body weight ratio
was determined.
(C–D) Tlr4WTwere either not gut sterilized (n = 7) or
gut sterilized 2 weeks after the last CCl4 injection
until they were sacrificed (n = 8). Livers were
stained for Ki-67 and cleaved-caspase 3 followed
by quantification (C). Correlation between the
number of cleaved-caspase 3 positive cells and
tumor number, size, and liver:body weight ratio
was determined (D).
(E) Nos2, Birc3, and Birc5 mRNA levels were
compared between livers from Tlr4WT (n = 12) and
Tlr4mut (n = 9) mice and between untreated wild-
type mice (WT, n = 9) and antibiotics-treated wild-
type mice (Abx, n = 6) Tlr4WT mice. Data are
represented as means ± SD. *p < 0.05.
See also Figure S6.
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The Intestinal Microbiota, TLR4, and HCCthe composition of the gut microbiome, with the exception of
one taxon whose abundance differed between LPS- and PBS-
treated mice but not between Tlr4WT and Tlr4mut mice.
In contrast to a previous study (Yu et al., 2010), we find no
significant contribution of the intestinal microbiota and TLR4 to
tumor initiation or purely genotoxic hepatocarcinogenesis
but demonstrate two distinct mechanisms through which the
intestinal microbiota and TLR4 promote HCC: In early stages,
TLR4 deficiency and gut sterilization decrease hepatic prolifera-
tion and fibrogenesis. Accordingly, gut sterilization or LPS infu-
sion given during early stages moderately decrease or increase
hepatocarcinogenesis, respectively. Our study provides evi-
dence that TLR4-dependent HCC promotion in the early phases
is predominantly mediated by TLR4-dependent secretion of
growth factors such as epiregulin by hepatic stellate cells.
Thus, hepatic stellate cells might provide a link between fibrosis
and HCC development by increasing growth factors. Based on512 Cancer Cell 21, 504–516, April 17, 2012 ª2012 Elsevier Inc.previous studies showing promotion of
growth factor signaling and tumor devel-
opment by ECM-rich and stiff environ-
ment (Levental et al., 2009; Samuel
et al., 2011), it is likely that growth
factors and ECM produced by hepatic
stellate cells synergize in tumor pro-
motion. Our results are consistent with
recent studies showing TLR4- and
MyD88/Trif-dependent regulation of epi-
regulin and regeneration after injury in
the intestine (Brandl et al., 2010; Hsu
et al., 2010). However, HCC reduction in
epiregulin-deficient mice was less pro-
nounced than in Tlr4mut or gut-sterilized
mice, suggesting that additional mecha-
nisms contribute to TLR4-dependent
HCC promotion.The most significant contribution of the intestinal microbiota in
our study occurred during later stages of hepatocarcinogenesis
independently of CCl4-induced upregulation of growth factors
and regenerative responses. These results are remarkably
similar to a previous study in which NF-kB inhibition at late, but
not early, stages reduced inflammation-associated HCC (Pikar-
sky et al., 2004). In line with this study, we detected decreased
induction of NF-kB regulated genes and an increased rate
of apoptosis in all groups that were protected from HCC devel-
opment. Accordingly, we found that the hepatocyte compart-
ment which had been unresponsive to LPS in healthy livers
became highly sensitive to LPS in DEN plus CCl4-injured livers.
The biological relevance of increased apoptosis for HCC devel-
opment is emphasized by the strong inverse correlation of tumor
number, tumor size, and liver:body weight ratio with cleaved-
caspase 3-positive cells in two sets of gut-sterilized mice and
in Tlr4mut mice. In addition to its role in Abcb4KO chronic liver
Cancer Cell
The Intestinal Microbiota, TLR4, and HCCinjury model (Pikarsky et al., 2004), hepatocellular NF-kB also
acts a promoter of hepatocarcinogenesis in lymphotoxin-driven
HCC (Haybaeck et al., 2009), suggesting a requirement for hepa-
tocellular NF-kB in HCC occurring in the setting of significant
inflammation. In contrast, hepatocellular inactivation of NF-kB
in genotoxic HCC models enhances hepatocarcinogenesis (He
et al., 2010; Maeda et al., 2005). Finally, the complete
but rather unphysiological absence of NF-kB activity by Nemo
or TAK1 deletion causes chronic hepatocyte injury, liver
cirrhosis, and spontaneous HCC (Bettermann et al., 2010; Inoku-
chi et al., 2010; Luedde et al., 2007). Thus, the presence of
inflammation and the degree of NF-kB inhibition appear to be
crucial factors that determine whether NF-kB promotes or
inhibits hepatocarcinogenesis.
The majority of apoptosis in our study occurred in nontumor
areas of the liver suggesting that prosurvival signals provided
by the intestinal microbiota and TLR4 are required for the
survival of tumor precursors and that apoptosis prevents the
development of tumor lesions rather than leading to regression
of already established tumors. Accordingly, we observed no
effect of gut sterilization on already established HCCs. These
results are consistent with previous findings that gene expres-
sion profiles in nontumor liver tissue, including gene sets related
to NF-kB, TNFa, and interferon signaling—all downstream
targets of TLR4—are crucial determinants of tumor recurrence,
whereas tumor profiles have no prognostic value (Hoshida et al.,
2008).
One important difference between our findings and many
previous studies is the tumor-promoting effect of inflammatory
signals in resident liver cells. Bone-marrow-derived cells such
as macrophages are abundant sources of inflammatory cyto-
kines and contribute to genotoxic HCC (Maeda et al., 2005).
Our studies in chimeric mice demonstrate that bone-marrow-
derived cells including hepatic macrophages do not mediate
the tumor-promoting effects of TLR4 in both acute and long-
term HCC models. Accordingly, we found that both hepatic
stellate cells and hepatocytes are targets of LPS in the liver
with TLR4 on hepatic stellate cells most likely mediating regen-
erative response after injury and TLR4 on hepatocytes prevent-
ing apoptosis of hepatocytes and premalignant cells. Oval cells
represent another potential target of LPS and LPS-induced
mediators such as TNFa (Brooling et al., 2005), but we found
only few areas with A6- and cytokeratin-positive cells typical
of oval cells in our tumor model and no influence of TLR4
status and gut sterilization on the number of these cells. Further
studies in mice with conditional TLR4 deletion are required
to distinguish the relative contribution of TLR4 expressed in
hepatocytes versus TLR4 expressed in hepatic stellate cells to
hepatocarcinogenesis.
Together with results from a previous study (Pikarsky et al.,
2004), our data suggest that chronic liver injury affects the resi-
dent liver compartment and makes resident liver cells and/or
tumor-forming cells more dependent on inflammatory signals
for their survival. With the majority of HCCs occurring in chroni-
cally injured livers but many mouse models lacking chronic
injury, it is possible that the contribution of inflammatory pathway
to human HCC has been underestimated. Our results differ from
a previous study in which bone-marrow-derived cell populations
were suggested to promote HCC through TLR4 (Yu et al., 2010).Notably, conclusions on the contribution of bone marrow were
based on acute responses to DEN instead of HCC development
in that study. Moreover, TLR4- and MyD88-dependent carcino-
genesis in the intestine and hepatic carcinogenesis in HCV
transgenic mice are also promoted by resident cells (Hsu et al.,
2010; Lee et al., 2010; Machida et al., 2009; Rakoff-Nahoum
and Medzhitov, 2007). In the latter study, TLR4 promotes HCC
in alcohol-treated HCV transgenic mice through the upregulation
of stem cell markers. Although we observed a strong increase in
the stem cell marker prominin 1/CD133 in HCCs, we observed
no influence of TLR4 status on its expression in our microarray
analysis, suggesting that there may be additional mechanisms
by which TLR4 promotes hepatocarcinogenesis in alcohol-
treated HCV transgenic mice.
To enable bone marrow transplantation studies in adult mice,
our study took advantage of the high HCC susceptibility of the
C3H strain and used Tlr4WT C3H/HeOuJ and Tlr4mut C3H/HeJ
mice. We can exclude that genetic differences besides TLR4
play a role in the observed promotion of HCC by TLR4 and the
intestinal microbiota based on the following findings: (a) The
Tlr4 locus is the only SNP among 2,059 tested SNPs that
differs between C3H/HeOuJ and C3H/HeJ mice (www.jax.org/
phenome). (b) Findings in C3H/HeOuJ and C3H/HeJ mice were
confirmed in wild-type and Tlr4KO C57Bl/6 mice. (c) A large set
of experiments solely performed in C3H/HeOuJ mice such as
gut sterilization and LPS infusion by osmotic pumps demon-
strated the HCC-promoting role for the intestinal microbiota
and the TLR4 ligand LPS.
The presented data provide conclusive evidence that the
intestinal microbiota exerts a profound influence on HCC
promotion in the chronically injured liver. Moreover, our study
provides a strong rationale for targeting the intestinal microbiota
and TLR4 for the primary or secondary prevention of HCC. The
astounding reduction of HCC by gut sterilization at late stages
suggests that these treatments might exert protective effects
even in advanced liver disease. HCC has become the major
cause of death in patients with compensated liver cirrhosis,
and there is a need for more effective treatment and preventa-
tive strategies (Bruix et al., 2004). To translate our findings into
clinical medicine, clinically feasible methods of targeting the
intestinal microbiota or TLR4 need to be established. The
quadruple combination of antibiotics used in the present study
almost completely decontaminated the intestine and prevented
80% of murine HCCs but is not suitable for long-term treatment
due to known side effects in patients with advanced liver
disease. Our study suggests that rifaximin, a nonabsorbable
antibiotic that is widely used in patients with advanced liver
disease (Bass et al., 2010), may moderately reduce HCC devel-
opment. Further studies are required to determine if longer
treatment duration or combination with other well-tolerated
antibiotics could improve the effects of rifaximin or if other
approaches such as TLR4 antagonists would reduce HCC
development.EXPERIMENTAL PROCEDURES
Mice: HCC Induction and Evaluation
C3H/HeOuJ, C3H/HeJ, TLR2-deficient mice, TLR4-deficient mice (C57Bl6/
10ScN), TNFR1-/IL-1R1-double deficient, and C57Bl/6 mice were purchasedCancer Cell 21, 504–516, April 17, 2012 ª2012 Elsevier Inc. 513
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The Intestinal Microbiota, TLR4, and HCCfrom Jackson Laboratories. Ereg-deficientmice in aC57Bl/6 backgroundwere
obtained from the Mouse Mutant Regional Resource Center at the University
of North Carolina.
In C3H/HeOuJ and C3H/HeJ mice, HCC was induced by intraperitoneal
(i.p.) injection of DEN (100 mg/kg) at ages 6-14 weeks followed by 6-12
biweekly injections of carbon tetrachloride (0.5 ml/kg i.p., dissolved in
corn oil) unless stated otherwise. For Ereg-deficient mice and C57Bl/6
wild-type controls, HCC was induced by the combination of DEN (25 mg/kg
i.p.) given at Day 15 postpartum and 22 weekly injections of CCl4 (0.5 ml/kg
i.p., dissolved in corn oil). For Tlr2KO mice and C57Bl/6 wild-type controls,
HCC was induced by the combination of DEN (100 mg/kg, i.p.) given at
the age of 8 weeks, followed by 25 biweekly injections of CCl4 (0.5 ml/kg,
i.p., dissolved in corn oil). Gut sterilization was done as previously described
(Rakoff-Nahoum et al., 2004; Seki et al., 2007) using a combination of
ampicillin (1 g/l), neomycin (1 g/l), metronidazole (1 g/l), and vancomycin
(500 mg/l) in drinking water. For rifaximin studies, mice received either
250 mg/l rifaximin in drinking water with rifaximin dissolved in Ora-Plus/
Ora-Sweet (Cober et al., 2010) or Ora-Plus/Ora-Sweet vehicle translating
to a rifaximin dose of 50 mg/kg/day. GF mouse experiments were performed
at the University of North Carolina National Gnotobiotic Rodent Resource
Center, Chapel Hill, NC. All mice received DEN (25 mg/kg i.p.) in the GF
status at Day 15 postpartum. One week after DEN, 50% of mice were
moved to an SPF environment. Four weeks after the DEN injection, GF
and SPF mice received a total of 10 CCl4 injections (1 injection per week,
at 0.5 ml/kg i.p. in corn oil). GF status was confirmed by biweekly monitoring
for the presence of bacteria in the feces by aerobic and anaerobic culture as
well as Gram staining of the stool. Mice were sacrificed 30 weeks after the
initial DEN injection.
Evaluation of tumor number and size was determined as described by
counting the number of visible tumors and measuring the size of the largest
tumor with a caliper (Naugler et al., 2007). After sacrifice, livers were explanted,
digitally photographed, and weighed to calculate the liver:body weight ratio.
To evaluate acute effects of TLR4 and the intestinal microbiota, adult mice
were treated with DEN (100 mg/kg i.p.) alone or in combination with either
two or four injections of CCl4 (0.5 ml/kg i.p.), two injections of thioacetamide
(400 mg/kg i.p.) or 4 weeks of a choline-deficient L-amino-acid-defined diet.
For some experiments, mice were treated with lipsomomal clodronate or
liposome vehicles (200 ml i.p.). For some experiments, liver fibrosis was
induced by ligating the common bile duct as previously described (Kluwe
et al., 2010; Seki et al., 2007). All animal procedures were in accordance
to guidelines by the National Institutes of Health and approved by the Institu-
tional Animal Care and Use Committee at Columbia University and the Institu-
tional Animal Care and Use Committee at the University of North Carolina,
Chapel Hill.Human Samples and Cells
Patients with clinical, analytical, and histological features of alcoholic hepatitis
were prospectively obtained in the Liver Unit of the Hospital Clı´nic, Barcelona,
between January 2009 and December 2010 (n = 10). Liver biopsies were
obtained using a transjugular approach. In all patients, liver specimens
were analyzed by an expert liver pathologist. Fragments of normal livers
were obtained from optimal cadaveric liver donors (n = 2) or resection of
liver metastases (n = 2). All controls had normal serum aminotransferase
levels and normal liver histology. Human hepatic stellate cells were isolated
by density gradient-based centrifugation from normal liver as described
(Kluwe et al., 2010) and used between passages 3 and 5. Procedures involving
human materials were approved by the Investigational Review Board of
the Hospital Clı´nic of Barcelona, and informed consent was obtained from
all subjects.Primary Cell Isolations
Primary hepatic stellate cells, Kupffer cells, and hepatocytes were isolated
from either normal or DEN plus 23 CCl4-treated mice using retrograde
liver perfusion and isolation techniques as previously described (Seki et al.,
2007). For some experiments, hepatic stellate cells were infected with an
adenovirus expressing IkB superrepressor (AdIkBsr) or an empty control
adenovirus as described elsewhere (Seki et al., 2007).514 Cancer Cell 21, 504–516, April 17, 2012 ª2012 Elsevier Inc.ACCESSION NUMBERS
Microarray information was deposited at the Gene Expression Omnibus
database (http://www.ncbi.nlm.nih.gov/geo/) with the accession number
GSE33446.
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